The current genetic biomarkers under investigation in NSCLC patients after ICB are outlined below, where analysis of the tumour mutational burden (TMB) is the second most investigated biomarker after PD‐L1 expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.